Impact BioMedical, Inc. (IBO)
4.68
-0.16
(-3.31%)
USD |
NYAM |
Oct 06, 16:00
4.61
-0.07
(-1.50%)
Pre-Market: 08:45
Impact BioMedical Gross Profit Margin (Quarterly) : -9.40K% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.40K% |
| March 31, 2026 | -3.97K% |
| December 31, 2025 | -10.01K% |
| September 30, 2025 | -1.51K% |
| June 30, 2025 | -4.17K% |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 |
| Date | Value |
|---|---|
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | -456.0% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| LENZ Therapeutics, Inc. | 94.90% |
| Enveric Biosciences, Inc. | -- |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 13.83% |
| Return on Assets | 4.13% |
| Return on Invested Capital | 5.29% |
| Profit Margin (Quarterly) | -23.33K% |
| Operating Margin (Quarterly) | -23.40K% |
| Return on Net Operating Assets | 4.44% |